News

See the latest updates from Biomendex

Pasi Kankaanpää starts as the CEO of Biomendex on the first of March 2023

Adaptos® clinical study started with Hospital Orton, Oral and Planmeca

Biomendex closed 1 M€ investment round

Biomendex held bone regeneration -seminar

More functional synthetic bone graft substitutes are developed with reliable porosity analysis and properly chosen analysis methods

EU to award Biomendex Oy up to €2,2M funding for entry to the orthopedic implant market

High porosity and bone attachment are crucial elements for a synthetic bone graft – study demonstrates the excellent properties of a novel composite material